Europäische Union - Deutsch - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , dreifach-kombinationstherapie) als ergänzung zu diät und bewegung bei patienten, die unzureichend kontrolliert auf ihren maximalen tolerierten dosis von metformin und sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europäische Union - Deutsch - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , dreifach-kombinationstherapie) als ergänzung zu diät und bewegung bei patienten, die unzureichend kontrolliert auf ihren maximalen tolerierten dosis von metformin und sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - metformini hydrochloridum, sitagliptinum - filmtabletten - metformini hydrochloridum 500 mg, sitagliptinum 50 mg ut sitagliptini hydrochloridum monohydricum, cellulosum microcristallinum, povidonum k 29-32, natrii laurilsulfas, natrii stearylis fumaras, Überzug: poly(alcohol vinylicus), e 171, macrogola, talcum, e 172 (flavum), e 172 (rubrum), pro compresso obducto corresp. natrium 1.025 mg. - diabetes typ 2 - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - metformini hydrochloridum, sitagliptinum - filmtabletten - metformini hydrochloridum 850 mg, sitagliptinum 50 mg ut sitagliptini hydrochloridum monohydricum, cellulosum microcristallinum, povidonum k 29-32, natrii laurilsulfas, natrii stearylis fumaras, Überzug: lactosum monohydricum 13.7 mg, hypromellosum, e 171, triacetinum, e 172 (rubrum), pro compresso obducto corresp. natrium 1.74 mg. - diabetes typ 2 - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - metformini hydrochloridum, sitagliptinum - filmtabletten - metformini hydrochloridum 1000 mg, sitagliptinum 50 mg ut sitagliptini hydrochloridum monohydricum, cellulosum microcristallinum, povidonum k 29-32, natrii laurilsulfas, natrii stearylis fumaras, Überzug: poly(alcohol vinylicus), macrogola, talcum, e 171, e 172 (rubrum), e 172 (nigrum), pro compresso obducto corresp. natrium 2.05 mg. - diabetes typ 2 - synthetika

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

ratiopharm arzneimittel vertriebs-gmbh - metformin hydrochlorid; sitagliptin hydrochlorid monohydrat -

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

ratiopharm arzneimittel vertriebs-gmbh - metformin hydrochlorid; sitagliptin hydrochlorid monohydrat -

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

actavis group ptc ehf. - metformin hydrochlorid; sitagliptin hydrochlorid monohydrat -

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

actavis group ptc ehf. - metformin hydrochlorid; sitagliptin hydrochlorid monohydrat -

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - metformini hydrochloridum, sitagliptinum - filmtabletten - metformini hydrochloridum 500 mg, sitagliptini hydrochloridum monohydricum corresp. sitagliptinum 50 mg, povidonum k 30, natrii laurilsulfas, cellulosum microcristallinum, carmellosum natricum conexum, natrii stearylis fumaras, Überzug: hypromellosum, hydroxypropylcellulosum, triethylis citras, e 171, talcum, e 172 (rubrum), pro compresso obducto corresp. natrium 1.84 mg. - orales antidiabetikum - synthetika